ArticleVaccines2024

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.

Juleen Gayed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.